<DOC>
	<DOCNO>NCT01198834</DOCNO>
	<brief_summary>A Randomized , Multi-Center , Double-Blind , Factorial , Comparator Placebo-Controlled Phase III Trial Evaluate Efficacy , Tolerability Safety MRX-7EAT Etodolac-Lidocaine Topical Patch Treatment Ankle Sprains</brief_summary>
	<brief_title>MRX-7EAT Etodolac-Lidocaine Topical Patch Treatment Ankle Sprains</brief_title>
	<detailed_description />
	<mesh_term>Ankle Injuries</mesh_term>
	<mesh_term>Sprains Strains</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Etodolac</mesh_term>
	<criteria>Inclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Subject sign informed consent form . 2 . Subject 14 year age old ( assent accord state law ) . 3 . Females child bear potential must negative pregnancy test use adequate method birth control . Adequate define either hormonal partner vasectomy least three month , , condom , IUD , abstinence prescribe birth control . Females may consider nonchildbearing postmenopausal least 1 year surgically sterile . 4 . Subject diagnosis uncomplicated acute soft tissue inversion injury ankle , Grade II classification ( defined American Academy Orthopaedic Surgeons ( AAOS ) , `` partial tearing ligament '' ) occur ≥ 6 hour ≤ 48 hour study entry . 5 . Subject Current Pain Intensity point flex ankle unwrap rat prior study entry ≥ 5 ≤ 8 NPRS ( 11 point ; range 0 10 ; anchor `` none '' `` severe '' ) . 6 . Subject willing able comply protocol . Exclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Females child bear potential use adequate method birth control breastfeeding ( adequate define either hormonal partner vasectomy least three month , prescribed birth control , condom , IUD , abstinence prescribe birth control ) . 2 . Subject Grade I ( `` slight stretch damage fiber ( fibril ) ligament '' ) Grade III ( `` complete tear ligament '' ) sprain strain , bilateral sprain strain , concomitant fracture open wound site sprain strain , serious injury , determine investigator ( e.g. , nerve damage , joint instability , tendon rupture ) ; surgical treatment require . Diagnosis Grade III indicate positive anterior drawer test positive talar tilt test exclusionary ( inability perform test ( ) exclusionary opinion investigator Grade III sprain suspect ) . 3 . Subject history previous injury area within two month prior current injury previous surgery area . 4 . Subject use nonpharmacologic treatment injury within 2 hour prior baseline visit ( e.g . ice acupuncture ) may interfere pain assessment . Subjects therapeutic exercise regimen continue base investigator 's discretion . Use iontophoresis prohibit . 5 . Subject use oral pharmacologic treatment ( NSAIDs analgesic medication ) injury less three halflives baseline assessment ; ibuprofen permit prior baseline long within six hour baseline assessment aspirin ( 81325 mg daily ) take prophylactically cardiovascular reason permit . 6 . Subject use form opioid within 24 hour study entry use opioids five consecutive day within 30 day precede screen visit . 7 . Subject receive systemic corticosteroid 30 day precede screen visit ( e.g. , intraarticular , peritendinous , oral , parenteral administration ) ; topical corticosteroid use acceptable unless applied target joint ; inhaled steroid acceptable ( e.g . Flonase® ) . 8 . Subject recently initiate sleep medication , muscle relaxant , anticonvulsant antidepressant ( within past 30 day ) ; use , subject must stable dose regimen 30 day prior study enrollment . 9 . Subject use TNF alpha blocker Class 1 antiarrhythmic drug within 60 day precede screen visit . 10 . Subject history physical assessment find clinically significant GI ulcer abnormal bleeding , anemia , kidney disease , liver disease , poorly control lung , stomach , heart , vital organ disease determine study investigator/physician . 11 . Subject history physical assessment find compatible safe participation study determine study investigator . 12 . Subject form inflammatory arthritis , spondyloarthropathies ( sPA ) , fibromyalgia , currently undergo treatment chronic pain ; history , evidence , underlie disease injured area , osteoarthritis gout . 13 . Subject pain medical problem , investigator 's opinion , may interfere pain measurement target joint . 14 . Subject active skin lesion disease intend site application study medication . Skin lesion include open wound , rash , papules vesicle ; abrasion , laceration break skin intend site patch application . 15 . Subject history allergy etodolac , NSAIDs , lidocaine , adhesive ( e.g . adhesive tape ) . 16 . Subject history prior fail treatment topical NSAIDs ( Flector® Patch Voltaren® Gel ) define repeat attempt within three month precede screen visit . 17 . Subject history drug alcohol abuse within past two year precede screen visit . 18 . Subject receive investigational drug product participate investigational drug study within period 30 day prior receive study medication . 19 . Subject schedule elective surgery invasive procedure period study participation . 20 . Subject workman 's compensation pending legal hearing associate injury . 21 . Subject refuse provide inform consent unwilling unable follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ankle sprain</keyword>
</DOC>